A new research review published in Frontiers in Immunology suggests that it’s time to rethink how fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare but potentially devastating pregnancy condition, is detected and treated.
The researchers outlined how advances in immunology, screening and treatment are reshaping the understanding of the disorder and highlighted missed opportunities for prevention.
Historically, FNAIT has been difficult to detect because most pregnancies show no warning signs until complications appear and there is no routine universal screening. The review argues that this gap means many cases are only diagnosed after a first affected pregnancy, when the risk of recurrence in future pregnancies is high.
Learn more about FNAIT prognosis
The article highlighted growing interest in population screening for platelet incompatibility, particularly for the most common antigen involved, HPA-1a. Early identification of at-risk pregnancies could allow preventative treatment before bleeding occurs.
Treatment strategies have also evolved. The authors describe antenatal therapy with intravenous immunoglobulin (IVIG) as the current cornerstone of prevention in high-risk pregnancies. Given weekly during pregnancy, IVIG can reduce antibody-mediated platelet destruction and significantly lower the risk of fetal bleeding.
The review also pointed to emerging research into improved risk prediction, better laboratory testing and the potential for targeted therapies. Together, these developments could move FNAIT care from reactive management toward proactive prevention.
For obstetricians, the authors emphasized the need for greater awareness and collaboration between specialists. Earlier recognition of risk factors, improved diagnostic pathways and consideration of screening programs could help prevent some of the most serious outcomes linked to the condition.
“We advocate for the consideration of national screening initiatives to help prevent severe complications and mitigate the long-term socioeconomic and healthcare burden of FNAIT,” the authors wrote.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
